Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. announced that its Board of Directors increased its size to 11 members and appointed Alex M. Azar II, former United States Secretary of Health and Human Services, as a Class III director effective September 12, 2025. His term will run until the 2027 Annual Meeting of Stockholders and until a successor is elected and qualified, or earlier death, resignation or removal.
Secretary Azar will serve on the Board’s nominating and corporate governance committee. As a non-employee director, he will receive standard compensation under Guardant Health’s Amended Non-Employee Director Compensation Program, including a stock option award and a restricted stock unit award, each valued at $362,500. Each award will vest one-fourth on the first anniversary of his appointment and the remainder in monthly installments over the following three years, subject to continued service. The company will also enter into its standard indemnification agreement with him, and disclosed that there are no related-party arrangements or transactions requiring reporting.
Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported selling a total of 300,000 shares of Common Stock on 2025-09-09 in open market or private transactions at reported weighted-average prices of $59.4447 and $59.9346 per share. After these sales, he directly holds 2,123,499 shares of common stock. The reported prices reflect weighted-average figures for multiple trades within ranges from $58.79 to $59.78 and from $59.79 to $60.25 per share.
Guardant Health, Inc. (GH) filed a Form 144 to notify a proposed sale of securities under Rule 144. The filing states that 300,000 shares of Common Stock are to be sold through Stifel Nicolaus & Company Inc. on or about 09/09/2025 on Nasdaq, with an aggregate market value of $17,835,990.00. The filer reports acquisition details for the shares: 286,065 shares from Restricted Stock Units acquired 01/07/2021 and 50,000 shares purchased on 11/19/2021, with cash noted as the payment method. The filer certifies no undisclosed material adverse information and provides the standard Rule 144 attestation.
Insider sale by Guardant Health director Meghan V. Joyce. The filing shows a sale of 100 shares of Guardant Health common stock on 09/02/2025 at a price of $65.84 per share. After the transaction Ms. Joyce beneficially owned 11,183 shares, held directly. The form indicates the sale was made pursuant to a 10b5-1 plan. The filing is signed by an attorney-in-fact on behalf of the reporting person.
John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on 09/01/2025. He received 264 restricted stock units that vested (reported as 264 shares acquired at $0), increasing his holdings to 45,087 shares. On the same date he disposed of 139 shares at a reported price of $67.42, leaving 44,948 shares beneficially owned after the transactions. The disclosure notes the RSU award was granted on November 2, 2021, with an initial 25% vesting on September 1, 2022, and the remaining 75% vesting quarterly over the following three years.
Guardant Health director and Chief Information Officer Kumud Kalia reported transactions on Form 4 showing restricted stock units vesting and a small open-market sale. On 09/01/2025, 711 shares were reported as acquired at a $0 price reflecting the vesting of RSUs, leaving 19,211 shares beneficially owned. The filing also shows a disposal of 361 shares on 09/01/2025 at a price of $67.42, reducing reported holdings to 18,850 shares. The RSU award was originally granted in November 2021 and vests quarterly through the three-year schedule that began 09/01/2022.
Darya Chudova, identified as Chief Technology Officer of Guardant Health, Inc. (GH), reported changes in beneficial ownership on a Form 4 filed for transactions dated 09/01/2025. The filing shows 316 restricted stock units deemed acquired at $0 (coded M) related to RSU vesting, and a reported disposition of 161 shares at $67.42. Following the transactions, the reporting person is shown as beneficially owning 81,610 shares after the acquisition line and 81,449 after the disposition line. The RSU award was originally granted on November 2, 2021 and fully vests on September 1, 2025, with vesting occurring in equal quarterly installments.
Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported acquisitions on Form 4 dated 08/31/2025. The filing shows a non-derivative entry and a derivative entry reflecting restricted stock units. The non-derivative entry records 155 shares acquired on 08/31/2025 at an aggregate price of $0, bringing his direct beneficial ownership of common stock to 18,128 shares. The derivative section shows 155 restricted stock units reported on 08/31/2025 with a $0 price, corresponding to 1,543 shares of common stock beneficially owned following the transaction on a direct basis. Explanatory notes state the RSU award was granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the following three years.
This Form 144 notice records a proposed sale of 100 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., with an aggregate market value of $6,584 and an approximate sale date of 09/02/2025. The filer reports acquiring the shares through restricted stock lapses: 34 shares on 06/12/2025 and 66 shares on 07/04/2025, both listed as equity compensation.
The filing also discloses sales by the same person within the past three months: 100 shares sold on 06/02/2025 for $4,166 and 3,337 shares sold on 06/13/2025 for $157,573. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Kumud Kalia, Chief Information Officer of Guardant Health (GH), reported a sale of 2,000 shares of the company's common stock on 08/21/2025 at a reported price of $61.755 per share. After this transaction the filing shows 18,500 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 08/22/2025 and discloses the officer role and timely reporting of the change in ownership.